

Alan F Schatzberg

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2117936/publications.pdf>

Version: 2024-02-01

158
papers

17,081
citations

25034

57
h-index

16183

124
g-index

168
all docs

168
docs citations

168
times ranked

18331
citing authors

#	ARTICLE	IF	CITATIONS
1	Resting-State Functional Connectivity in Major Depression: Abnormally Increased Contributions from Subgenual Cingulate Cortex and Thalamus. <i>Biological Psychiatry</i> , 2007, 62, 429-437.	1.3	1,979
2	Resting-state connectivity biomarkers define neurophysiological subtypes of depression. <i>Nature Medicine</i> , 2017, 23, 28-38.	30.7	1,554
3	Genome-wide association study identifies 30 loci associated with bipolar disorder. <i>Nature Genetics</i> , 2019, 51, 793-803.	21.4	1,191
4	A Comparison of Nefazodone, the Cognitive Behavioral-Analysis System of Psychotherapy, and Their Combination for the Treatment of Chronic Depression. <i>New England Journal of Medicine</i> , 2000, 342, 1462-1470.	27.0	1,188
5	Major depressive disorder. <i>Nature Reviews Disease Primers</i> , 2016, 2, 16065.	30.5	1,171
6	Circadian patterns of gene expression in the human brain and disruption in major depressive disorder. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2013, 110, 9950-9955.	7.1	477
7	A Consensus Statement on the Use of Ketamine in the Treatment of Mood Disorders. <i>JAMA Psychiatry</i> , 2017, 74, 399.	11.0	433
8	Attenuation of Antidepressant Effects of Ketamine by Opioid Receptor Antagonism. <i>American Journal of Psychiatry</i> , 2018, 175, 1205-1215.	7.2	338
9	Stanford Accelerated Intelligent Neuromodulation Therapy for Treatment-Resistant Depression. <i>American Journal of Psychiatry</i> , 2020, 177, 716-726.	7.2	321
10	An open label trial of C-1073 (mifepristone) for psychotic major depression*. <i>Biological Psychiatry</i> , 2002, 52, 386-392.	1.3	302
11	Rapid Reversal of Psychotic Depression Using Mifepristone. <i>Journal of Clinical Psychopharmacology</i> , 2001, 21, 516-521.	1.4	256
12	Corticosteroids and cognition. <i>Journal of Psychiatric Research</i> , 2001, 35, 127-145.	3.1	247
13	Double-blind, placebo-controlled, dose-ranging trial of intravenous ketamine as adjunctive therapy in treatment-resistant depression (TRD). <i>Molecular Psychiatry</i> , 2020, 25, 1592-1603.	7.9	235
14	Stanford Neuromodulation Therapy (SNT): A Double-Blind Randomized Controlled Trial. <i>American Journal of Psychiatry</i> , 2022, 179, 132-141.	7.2	233
15	A corticosteroid/dopamine hypothesis for psychotic depression and related states. <i>Journal of Psychiatric Research</i> , 1985, 19, 57-64.	3.1	232
16	Prevalence of Depressive Episodes With Psychotic Features in the General Population. <i>American Journal of Psychiatry</i> , 2002, 159, 1855-1861.	7.2	230
17	Glucocorticoid and mineralocorticoid receptor mRNA expression in squirrel monkey brain. <i>Journal of Psychiatric Research</i> , 2000, 34, 383-392.	3.1	216
18	Clinical and Biological Effects of Mifepristone Treatment for Psychotic Depression. <i>Neuropsychopharmacology</i> , 2006, 31, 628-636.	5.4	198

#	ARTICLE	IF	CITATIONS
19	Neuropsychological Deficits in Psychotic Versus Nonpsychotic Major Depression and No Mental Illness. <i>American Journal of Psychiatry</i> , 2000, 157, 1095-1100.	7.2	192
20	24-Hour Monitoring of Cortisol and Corticotropin Secretion in Psychotic and Nonpsychotic Major Depression. <i>Archives of General Psychiatry</i> , 2000, 57, 755.	12.3	187
21	Cortisol Circadian Rhythm Alterations in Psychotic Major Depression. <i>Biological Psychiatry</i> , 2006, 60, 275-281.	1.3	180
22	Successful Long-Term Treatment of Refractory Cushing's Disease with High-Dose Mifepristone (RU 3647) Overlock 10	3.6	167
23	Cortisol Activity and Cognitive Changes in Psychotic Major Depression. <i>American Journal of Psychiatry</i> , 2001, 158, 1612-1616.	7.2	154
24	Post-mortem molecular profiling of three psychiatric disorders. <i>Genome Medicine</i> , 2017, 9, 72.	8.2	147
25	Chronic Depression. <i>Archives of General Psychiatry</i> , 2005, 62, 513.	12.3	139
26	Depression Subtypes in Predicting Antidepressant Response: A Report From the iSPOT-D Trial. <i>American Journal of Psychiatry</i> , 2015, 172, 743-750.	7.2	138
27	High-dose spaced theta-burst TMS as a rapid-acting antidepressant in highly refractory depression. <i>Brain</i> , 2018, 141, e18-e18.	7.6	138
28	Ketamine: Promising Path or False Prophecy in the Development of Novel Therapeutics for Mood Disorders?. <i>Neuropsychopharmacology</i> , 2015, 40, 259-267.	5.4	132
29	Neurobiological Signatures of Anxiety and Depression in Resting-State Functional Magnetic Resonance Imaging. <i>Biological Psychiatry</i> , 2015, 77, 385-393.	1.3	130
30	A Double-Blind, Randomized Study of Olanzapine and Olanzapine/Fluoxetine Combination for Major Depression With Psychotic Features. <i>Journal of Clinical Psychopharmacology</i> , 2004, 24, 365-373.	1.4	128
31	Randomized Clinical Trial of the Efficacy of Bupropion Combined With Nicotine Patch in the Treatment of Adolescent Smokers.. <i>Journal of Consulting and Clinical Psychology</i> , 2004, 72, 729-735.	2.0	126
32	Double-blind Switch Study of Imipramine or Sertraline Treatment of Antidepressant-Resistant Chronic Depression. <i>Archives of General Psychiatry</i> , 2002, 59, 233.	12.3	123
33	The International Study to Predict Optimized Treatment in Depression (iSPOT-D): Outcomes from the acute phase of antidepressant treatment. <i>Journal of Psychiatric Research</i> , 2015, 61, 1-12.	3.1	121
34	A Double-Blind, Placebo-Controlled Study of Venlafaxine and Fluoxetine in Geriatric Outpatients With Major Depression. <i>American Journal of Geriatric Psychiatry</i> , 2006, 14, 361-370.	1.2	116
35	The Neuropsychological Profile of Psychotic Major Depression and its Relation to Cortisol. <i>Biological Psychiatry</i> , 2006, 60, 472-478.	1.3	110
36	A Cognitive "Emotional Biomarker for Predicting Remission with Antidepressant Medications: A Report from the iSPOT-D Trial. <i>Neuropsychopharmacology</i> , 2015, 40, 1332-1342.	5.4	101

#	ARTICLE	IF	CITATIONS
37	The effects of a single acute dose of dexamethasone on monoamine and metabolite levels in rat brain. <i>Life Sciences</i> , 1985, 36, 2491-2501.	4.3	100
38	Attenuation of antidepressant and antisuicidal effects of ketamine by opioid receptor antagonism. <i>Molecular Psychiatry</i> , 2019, 24, 1779-1786.	7.9	100
39	Efficacy and Safety of Agomelatine in the Treatment of Major Depressive Disorder. <i>Journal of Clinical Psychopharmacology</i> , 2010, 30, 135-144.	1.4	98
40	Current Issues in the Classification of Psychotic Major Depression. <i>Schizophrenia Bulletin</i> , 2007, 33, 877-885.	4.3	93
41	Relationships between brain ct scan findings and cortisol in psychotic and nonpsychotic depressed patients. <i>Biological Psychiatry</i> , 1989, 26, 565-575.	1.3	91
42	Neuropsychological correlates of psychotic features in major depressive disorders: a review and meta-analysis. <i>Journal of Psychiatric Research</i> , 2004, 38, 27-35.	3.1	91
43	Postnatal foraging demands alter adrenocortical activity and psychosocial development. <i>Developmental Psychobiology</i> , 1998, 32, 285-291.	1.6	84
44	A Word to the Wise About Ketamine. <i>American Journal of Psychiatry</i> , 2014, 171, 262-264.	7.2	82
45	Plasma oxytocin concentrations are lower in depressed vs. healthy control women and are independent of cortisol. <i>Journal of Psychiatric Research</i> , 2014, 51, 30-36.	3.1	79
46	Evidence for alterations of the glial syncytial function in major depressive disorder. <i>Journal of Psychiatric Research</i> , 2016, 72, 15-21.	3.1	79
47	Gene Expression Changes in the Prefrontal Cortex, Anterior Cingulate Cortex and Nucleus Accumbens of Mood Disorders Subjects That Committed Suicide. <i>PLoS ONE</i> , 2012, 7, e35367.	2.5	77
48	Clozapine response and plasma catecholamines and their metabolites. <i>Psychiatry Research</i> , 1993, 46, 139-149.	3.3	75
49	Aberrant Brain Activation During a Working Memory Task in Psychotic Major Depression. <i>American Journal of Psychiatry</i> , 2011, 168, 173-182.	7.2	75
50	The Dexamethasone Suppression Test as a Discriminator among Subtypes of Psychotic Patients. <i>British Journal of Psychiatry</i> , 1982, 141, 471-474.	2.8	72
51	ABCB1 Genetic Effects on Antidepressant Outcomes: A Report From the iSPOT-D Trial. <i>American Journal of Psychiatry</i> , 2015, 172, 751-759.	7.2	69
52	Dexamethasone increases plasma free dopamine in man. <i>Journal of Psychiatric Research</i> , 1984, 18, 217-223.	3.1	68
53	A Word to the Wise About Intranasal Esketamine. <i>American Journal of Psychiatry</i> , 2019, 176, 422-424.	7.2	68
54	A Delphi-method-based consensus guideline for definition of treatment-resistant depression for clinical trials. <i>Molecular Psychiatry</i> , 2022, 27, 1286-1299.	7.9	68

#	ARTICLE	IF	CITATIONS
55	G protein-linked signaling pathways in bipolar and major depressive disorders. <i>Frontiers in Genetics</i> , 2013, 4, 297.	2.3	67
56	fMRI Activation During Executive Function Predicts Response to Cognitive Behavioral Therapy in Older, Depressed Adults. <i>American Journal of Geriatric Psychiatry</i> , 2015, 23, 13-22.	1.2	66
57	Inference of cell type content from human brain transcriptomic datasets illuminates the effects of age, manner of death, dissection, and psychiatric diagnosis. <i>PLoS ONE</i> , 2018, 13, e0200003.	2.5	65
58	The microRNA network is altered in anterior cingulate cortex of patients with unipolar and bipolar depression. <i>Journal of Psychiatric Research</i> , 2016, 82, 58-67.	3.1	61
59	Combined Analysis of Mifepristone for Psychotic Depression: Plasma Levels Associated With Clinical Response. <i>Biological Psychiatry</i> , 2018, 84, 46-54.	1.3	61
60	Slowing the progression of cognitive decline in Alzheimer's disease using mifepristone. <i>Journal of Molecular Neuroscience</i> , 2002, 19, 201-206.	2.3	60
61	Sertraline versus imipramine to prevent relapse in chronic depression. <i>Journal of Affective Disorders</i> , 2001, 65, 27-36.	4.1	58
62	Psychotic and nonpsychotic depressions: I. comparisons of plasma catecholamines and cortisol measures. <i>Psychiatry Research</i> , 1987, 20, 143-153.	3.3	56
63	A pilot study of the phase angle between cortisol and melatonin in major depression – A potential biomarker?. <i>Journal of Psychiatric Research</i> , 2010, 44, 69-74.	3.1	56
64	Glucocorticoid antagonists in neuropsychotic disorders. <i>European Journal of Pharmacology</i> , 2008, 583, 358-364.	3.5	55
65	NMDA antagonist treatment of depression. <i>Current Opinion in Neurobiology</i> , 2016, 36, 112-117.	4.2	55
66	Effects of major depression diagnosis and cortisol levels on indices of neurocognitive function. <i>Psychoneuroendocrinology</i> , 2009, 34, 1012-1018.	2.7	50
67	FKBP5 polymorphisms and antidepressant response in geriatric depression. <i>American Journal of Medical Genetics Part B: Neuropsychiatric Genetics</i> , 2010, 153B, 554-560.	1.7	50
68	Human amygdala engagement moderated by early life stress exposure is a biobehavioral target for predicting recovery on antidepressants. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 11955-11960.	7.1	50
69	Fibroblast growth factor 9 is a novel modulator of negative affect. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2015, 112, 11953-11958.	7.1	49
70	HPA axis in psychotic major depression and schizophrenia spectrum disorders: Cortisol, clinical symptomatology, and cognition. <i>Schizophrenia Research</i> , 2019, 213, 72-79.	2.0	47
71	Glucocorticoid Effects on Mesotelencephalic Dopamine Neurotransmission. <i>Neuropsychopharmacology</i> , 1999, 21, 399-407.	5.4	45
72	The mineralocorticoid receptor agonist, fludrocortisone, differentially inhibits pituitary-adrenal activity in humans with psychotic major depression. <i>Psychoneuroendocrinology</i> , 2013, 38, 115-121.	2.7	45

#	ARTICLE	IF	CITATIONS
73	Anna-Monika Award Lecture, DGPPN Kongress, 2013: The role of the hypothalamicâ€”pituitaryâ€”adrenal (HPA) axis in the pathogenesis of psychotic major depression. World Journal of Biological Psychiatry, 2015, 16, 2-11.	2.6	44
74	Prefrontal networks dynamically related to recovery from major depressive disorder: a longitudinal pharmacological fMRI study. Translational Psychiatry, 2019, 9, 64.	4.8	43
75	The Roles of Glucocorticoid and Dopaminergic Systems in Delusional (Psychotic) Depression. Annals of the New York Academy of Sciences, 1988, 537, 462-471.	3.8	40
76	Altered choroid plexus gene expression in major depressive disorder. Frontiers in Human Neuroscience, 2014, 8, 238.	2.0	40
77	Decreased Hypothalamic Functional Connectivity with Subgenual Cortex in Psychotic Major Depression. Neuropsychopharmacology, 2015, 40, 849-860.	5.4	40
78	Antidepressant Outcomes Predicted by Genetic Variation in Corticotropin-Releasing Hormone Binding Protein. American Journal of Psychiatry, 2018, 175, 251-261.	7.2	39
79	Mitochondrial Mutations in Subjects with Psychiatric Disorders. PLoS ONE, 2015, 10, e0127280.	2.5	39
80	Double-blind, randomized comparison of mirtazapine and paroxetine in elderly depressed patients. American Journal of Geriatric Psychiatry, 2002, 10, 541-50.	1.2	38
81	Mesotelencephalic dopamine neurochemical responses to glucocorticoid administration and adrenalectomy in Fischer 344 and Lewis rats. Brain Research, 2002, 958, 414-422.	2.2	36
82	Withdrawal symptoms over time among adolescents in a smoking cessation intervention: Do symptoms vary by level of nicotine dependence?. Addictive Behaviors, 2009, 34, 1017-1022.	3.0	36
83	Mifepristone Plasma Level and Glucocorticoid Receptor Antagonism Associated With Response in Patients With Psychotic Depression. Journal of Clinical Psychopharmacology, 2017, 37, 505-511.	1.4	35
84	Developing a clinical translational neuroscience taxonomy for anxiety and mood disorder: protocol for the baseline-follow up Research domain criteria Anxiety and Depression (â€œRADâ€) project. BMC Psychiatry, 2016, 16, 68.	2.6	33
85	Pharmacological principles of antidepressant efficacy. Human Psychopharmacology, 2002, 17, S17-S22.	1.5	32
86	Mitochondrial Complex I Deficiency in Schizophrenia and Bipolar Disorder and Medication Influence. Molecular Neuropsychiatry, 2017, 3, 157-169.	2.9	31
87	Altered brain function underlying verbal memory encoding and retrieval in psychotic major depression. Psychiatry Research - Neuroimaging, 2013, 211, 119-126.	1.8	30
88	Detecting psychotic major depression using psychiatric rating scales. Journal of Psychiatric Research, 2006, 40, 22-29.	3.1	29
89	Side Effects to Antidepressant Treatment in Patients With Depression and Comorbid Panic Disorder. Journal of Clinical Psychiatry, 2017, 78, 433-440.	2.2	29
90	Cognitive and emotional biomarkers of melancholic depression: An iSPOT-D report. Journal of Affective Disorders, 2015, 176, 141-150.	4.1	28

#	ARTICLE	IF	CITATIONS
91	WHITHER KETAMINE AS AN ANTIDEPRESSANT: PANACEA OR TOXIN?. Depression and Anxiety, 2016, 33, 685-688.	4.1	26
92	Baseline cortisol and the efficacy of antiglucocorticoid treatment in mood disorders: A meta-analysis. Psychoneuroendocrinology, 2019, 110, 104420.	2.7	25
93	Hypothalamic-pituitary-adrenal axis effects on plasma homovanillic acid in man. Biological Psychiatry, 1999, 45, 222-228.	1.3	24
94	Coping and glucocorticoid receptor regulation by stress inoculation. Psychoneuroendocrinology, 2014, 49, 272-279.	2.7	23
95	Acute and delayed effects of corticotropin-releasing hormone on dopamine activity in man. Biological Psychiatry, 1994, 36, 616-621.	1.3	22
96	Splice-Break: exploiting an RNA-seq splice junction algorithm to discover mitochondrial DNA deletion breakpoints and analyses of psychiatric disorders. Nucleic Acids Research, 2019, 47, e59-e59.	14.5	22
97	Dilative cardiomyopathy leading to congestive heart failure in a male squirrel monkey (Saimiri) Tj ETQq1 1 0.784314 rgBT /Overlock 10T 0.6 21		
98	Cannabis and the Developing Adolescent Brain. Current Treatment Options in Psychiatry, 2020, 7, 144-161.	1.9	20
99	Strain differences in mesotelencephalic dopaminergic neuronal regulation between Fischer 344 and Lewis rats. Brain Research, 1999, 832, 152-158.	2.2	19
100	Intrinsic reward circuit connectivity profiles underlying symptom and quality of life outcomes following antidepressant medication: a report from the iSPOT-D trial. Neuropsychopharmacology, 2021, 46, 809-819.	5.4	18
101	The Acute and Post-Discontinuation Effects of a Glucocorticoid Receptor (GR) Antagonist Probe on Sleep and the HPA Axis in Chronic Insomnia: A Pilot Study. Journal of Clinical Sleep Medicine, 2008, 04, 235-241.	2.6	18
102	New approaches to managing psychotic depression. Journal of Clinical Psychiatry, 2003, 64 Suppl 1, 19-23.	2.2	18
103	Antidepressant discontinuation syndrome: consensus panel recommendations for clinical management and additional research. Journal of Clinical Psychiatry, 2006, 67 Suppl 4, 27-30.	2.2	18
104	Response to Transdermal Selegiline Smoking Cessation Therapy and Markers in the 15q24 Chromosomal Region. Nicotine and Tobacco Research, 2015, 17, 1126-1133.	2.6	17
105	Impairment and distress patterns distinguishing the melancholic depression subtype: An iSPOT-D report. Journal of Affective Disorders, 2015, 174, 493-502.	4.1	16
106	Development of New Psychopharmacological Agents for Depression and Anxiety. Psychiatric Clinics of North America, 2015, 38, 379-393.	1.3	16
107	Nonlinear relationship between early life stress exposure and subsequent resilience in monkeys. Scientific Reports, 2019, 9, 16232.	3.3	16
108	Identification of potential blood biomarkers associated with suicide in major depressive disorder. Translational Psychiatry, 2022, 12, 159.	4.8	16

#	ARTICLE	IF	CITATIONS
109	Toward a Biochemical Classification of Depressive Disorders IX. <i>British Journal of Psychiatry</i> , 1985, 146, 633-637.	2.8	15
110	Scientific Issues Relevant to Improving the Diagnosis, Risk Assessment, and Treatment of Major Depression. <i>American Journal of Psychiatry</i> , 2019, 176, 342-347.	7.2	15
111	Corticotropin-releasing factor 1 receptor haplotype and cognitive features of major depression. <i>Translational Psychiatry</i> , 2018, 8, 5.	4.8	14
112	Understanding the Clinical Effects and Mechanisms of Action of Neurosteroids. <i>American Journal of Psychiatry</i> , 2021, 178, 221-223.	7.2	14
113	Connective Tissue Growth Factor Is a Novel Prodepressant. <i>Biological Psychiatry</i> , 2018, 84, 555-562.	1.3	12
114	The Hypothalamic-Pituitary-Adrenal Axis in Alcoholics. <i>Alcoholism: Clinical and Experimental Research</i> , 1983, 7, 35-41.	2.4	11
115	Rigorous Trial Design Is Essential to Understand the Role of Opioid Receptors in Ketamine's Antidepressant Effect. <i>JAMA Psychiatry</i> , 2019, 76, 657.	11.0	11
116	Issues encountered in recent attempts to develop novel antidepressant agents. <i>Annals of the New York Academy of Sciences</i> , 2015, 1345, 67-73.	3.8	10
117	Some Comments on Psychedelic Research. <i>American Journal of Psychiatry</i> , 2020, 177, 368-369.	7.2	10
118	Understanding the Efficacy and Mechanism of Action of a Dextromethorphan-Bupropion Combination: Where Does It Fit in the NMDA Versus mu-Opioid Story?. <i>American Journal of Psychiatry</i> , 2022, 179, 448-450.	7.2	9
119	Mechanisms of Action of Ketamine and Esketamine. <i>American Journal of Psychiatry</i> , 2021, 178, 1130-1130.	7.2	8
120	The relationship of chronic pain and depression. <i>Journal of Clinical Psychiatry</i> , 2004, 65 Suppl 12, 3-4.	2.2	8
121	Safety and tolerability of antidepressants: weighing the impact on treatment decisions. <i>Journal of Clinical Psychiatry</i> , 2007, 68 Suppl 8, 26-34.	2.2	8
122	Reply: Clinical and Biological Effects of Mifepristone Treatment for Psychotic Treatment. <i>Neuropsychopharmacology</i> , 2006, 31, 2795-2797.	5.4	7
123	Striatal dopamine D2/3 receptor regulation by stress inoculation in squirrel monkeys. <i>Neurobiology of Stress</i> , 2016, 3, 68-73.	4.0	7
124	Learning to cope with stress modulates anterior cingulate cortex stargazin expression in monkeys and mice. <i>Neurobiology of Learning and Memory</i> , 2016, 131, 95-100.	1.9	7
125	Stress amplifies sex differences in primate prefrontal profiles of gene expression. <i>Biology of Sex Differences</i> , 2017, 8, 36.	4.1	7
126	Learning to actively cope with stress in female mice. <i>Psychoneuroendocrinology</i> , 2018, 96, 78-83.	2.7	7

#	ARTICLE	IF	CITATIONS
127	More Thoughts on Intranasal Esketamine: Response to Drevets et al.. American Journal of Psychiatry, 2019, 176, 858-859.	7.2	7
128	Interpreting Ketamine's Opioid Receptor Dependent Effect: Response to Sanacora. American Journal of Psychiatry, 2019, 176, 249-250.	7.2	7
129	Unraveling the opioid actions of S-ketamine and R-ketamine: comment on Bonaventura et al.. Molecular Psychiatry, 2021, 26, 6104-6106.	7.9	7
130	Rapid Detection of the C ⁺ 1496G Polymorphism in the CYP2D6 *2 Allele. Clinical Chemistry, 2001, 47, 2153-2155.	3.2	6
131	Neural cell adhesion molecule peptide mimetics modulate emotionality: pharmacokinetic and behavioral studies in rats and non-human primates. Neuropsychopharmacology, 2019, 44, 356-363.	5.4	6
132	Cross-Sectional Associations Among Symptoms of Pain, Irritability, and Depression and How These Symptoms Relate to Social Functioning and Quality of Life. Journal of Clinical Psychiatry, 2021, 82, .	2.2	6
133	Efficacy and tolerability of duloxetine, a novel dual reuptake inhibitor, in the treatment of major depressive disorder. Journal of Clinical Psychiatry, 2003, 64 Suppl 13, 30-7.	2.2	6
134	New Paradigm for Treating Recurrent Depression: From Symptom Control to Managing Enduring Vulnerabilities. CNS Spectrums, 2006, 11, 22-27.	1.2	5
135	Empirical evidence of the effect of personality pathology on the outcome of panic disorder. Journal of Psychiatric Research, 2018, 107, 42-47.	3.1	5
136	Target Population, Dose, and Timing Considerations for Understanding Naltrexone's Subjective Effect: Response to Amiaz. American Journal of Psychiatry, 2019, 176, 251-252.	7.2	4
137	Employing pharmacologic treatment of bipolar disorder to greatest effect. Journal of Clinical Psychiatry, 2004, 65 Suppl 15, 15-20.	2.2	4
138	Achieving Remission and Favorable Outcomes in Patients with Depression/Anxiety and Substance use Disorders. CNS Spectrums, 2008, 13, 10-12.	1.2	3
139	More Research Needed on the Association Between Genotype and Antidepressant Response: Response to Fabbri et al.. American Journal of Psychiatry, 2018, 175, 576-577.	7.2	3
140	Can Target Engagement Studies Miss Their Targets and Mislead Drug Development?. American Journal of Psychiatry, 2021, 178, 372-374.	7.2	3
141	Acute and delayed effects of adrenocorticotrophic hormone on dopamine activity in man. Depression, 1994, 2, 292-296.	0.6	2
142	Constance E. Lieber, Theodore R. Stanley, and the Enduring Impact of Philanthropy on Psychiatry Research. Biological Psychiatry, 2016, 80, 84-86.	1.3	2
143	Diagnostic differences in verbal learning strategies and verbal memory in patients with mood disorders and psychotic disorders. Psychiatry Research, 2018, 269, 733-739.	3.3	2
144	Multisensory modulation of body ownership in mice. Neuroscience of Consciousness, 2020, 2020, niz019.	2.6	2

#	ARTICLE	IF	CITATIONS
145	Prevalence, Factor Structure, and Heritability of Avoidant Personality Disorder. <i>Journal of Nervous and Mental Disease</i> , 2021, 209, 764-772.	1.0	2
146	Bridging the clinical gap: managing patients with co-occurring mood, anxiety, and alcohol use disorders. Introduction. <i>CNS Spectrums</i> , 2008, 13, 3.	1.2	2
147	Rigorous Translational Models Are Key to Studying Ketamine's Antidepressant Mechanism: Response to Wang and Kaplin. <i>American Journal of Psychiatry</i> , 2019, 176, 412-412.	7.2	1
148	The Black Book of Psychotropic Dosing and Monitoring. <i>Psychopharmacology Bulletin</i> , 2018, 48, 64-153.	0.0	1
149	Clinical use of nefazodone in major depression: a 6-year perspective. <i>Journal of Clinical Psychiatry</i> , 2002, 63 Suppl 1, 18-31.	2.2	1
150	Introduction: treating depression and anxiety to remission. <i>Journal of Clinical Psychiatry</i> , 2003, 64 Suppl 15, 3-4.	2.2	1
151	Commentary 6. <i>Pharmacotherapy</i> , 1984, 4, 324-324.	2.6	0
152	The silver lining of recent effectiveness trials. <i>World Psychiatry</i> , 2009, 8, 30-32.	10.4	0
153	Response to the Presidential Address. <i>American Journal of Psychiatry</i> , 2009, 166, 1105-1107.	7.2	0
154	Eberhard H Uhlenhuth. <i>Neuropsychopharmacology</i> , 2016, 41, 3127-3127.	5.4	0
155	In Memoriam of George Gardos, MD. <i>Neuropsychopharmacology</i> , 2020, 45, 1080-1080.	5.4	0
156	Comment on "Understanding the Clinical Effects and Mechanisms of Action of Neurosteroids": Response to Rubinow et al.. <i>American Journal of Psychiatry</i> , 2021, 178, 573-574.	7.2	0
157	Neurobiologic Foundations of Mood Disorders. , 0, , 339-353.		0
158	Pharmacologic treatments of major depression: are two mechanisms really better than one?. <i>Journal of Clinical Psychiatry</i> , 2004, 65 Suppl 4, 3-4.	2.2	0